Int erest in the potential role of PET with several radiotracers targeted to the underlying complex biology of prostate cancer has been increasing. The Warburg effect is a hallmark of cancer and can be reliably interrogated with PET and 18 F-FDG. In fact, 18 F-FDG PET has now become the mainstay for the imaging evaluation of several cancers. Another important biologic feature in cancer is cellular proliferation. The imaging of cellular proliferation can allow for tumor characterization and early objective assessment of the response to therapy. This article summarizes experience with the utility and limitations of PET for the imaging examination of glucose metabolism and cellular proliferation in prostate cancer.
GLUCOSE METABOLISM
It has often been stated that 18 F-FDG PET is not useful in prostate cancer. However, this belief seems to have arisen from some early studies in which 18 F-FDG PET was interrogated in the setting of primary tumor diagnosis or staging of the disease, for which the overall results were unsatisfactory (1) (2) (3) . The utility of 18 F-FDG PET appears to depend on the phase of the disease; therefore, it may be quite relevant in one phase of the disease but limited in another phase (4, 5) .
Incidental High Prostatic 18 F-FDG Uptake in Primary Cancer Detection
Reesink et al. assessed the clinical relevance of incidental prostatic lesions with 18 F-FDG PET and whether the findings should prompt additional evaluations (6) . That investigation involved 108 consecutive men who had bladder cancer and underwent radical cystoprostatectomy. Incidental prostatic uptake was noted in 40% of the cohort; overall, occult prostate cancers were found in 23% of the surgical specimens. The positive and negative predictive values for findings labeled as suspect or indeterminate for prostate cancer were 29% and 79%, respectively. However, the authors' final conclusions were that overall incidental prostatic uptake on 18 F-FDG PET/CT had a low positive predictive value for prostate cancer and that the Gleason score did not correlate with the SUV max or serum prostate-specific antigen (PSA).
In another study, involving 6,128 male patients who had undergone 18 F-FDG PET scans, incidental prostatic 18 F-FDG uptake was noted in 1.3% of the patients (7). There was no significant correlation between SUV max or serum PSA levels and whether the lesions were benign or malignant. Brown et al. reported that focal incidental prostatic uptake with an SUV max of greater than 6 should be further evaluated with multiparametric MRI (8) . A recent systematic review and metaanalysis of 47,925 men in 6 studies reported a pooled prevalence of 1.8% (95% confidence interval [CI], 1.3%-2.3%) for incidental high 18 F-FDG uptake in the prostate gland (9) . The pooled risks of malignancy in patients who were further evaluated or underwent biopsy (444 patients with incidental prostatic uptake underwent further evaluation and 121 patients underwent biopsy) were 17% (95% CI, 12%-23%) and 62% (95% CI, 54%-71%), respectively. Kang et al. suggested that incidental prostatic uptake on 18 F-FDG PET scans should not be ignored and that further investigation, such as PSA determination or additional imaging, should be undertaken; they made this suggestion despite the realization that the level of 18 F-FDG accumulation can overlap in normal prostate, benign prostatic hyperplasia, and prostate cancer tissues, which often coexist (10 18 F-FDG uptake and 99 of these men underwent prostate biopsy (11) . Prostate cancer occurred in 3.8% of men with serum PSA levels of less than 2.5 ng/mL and in 59.7% of men with serum PSA levels of greater than or equal to 2.5 ng/mL. Multivariable analysis showed that focal lesions (odds ratio, 5.50; P 5 0.038), age (odds ratio, 1.06; P 5 0.031), and serum PSA levels (odds ratio, 1.28; P 5 0.001) were independent predictors of prostate cancer diagnosis. The authors concluded that patients with high 18 F-FDG uptake in the prostate should be further evaluated by the measurement of serum PSA and that those with high serum PSA levels should be considered for prostate biopsy. In another Japanese investigation, an incidental prostatic 18 F-FDG uptake of 2% in 3,236 cases was reported (12) . In the evaluable 49 cases, 16% had prostate cancer, whereas 84% were benign.
Initial Staging
There are few data on the use of 18 F-FDG PET/CT for the initial staging of prostate cancer, given the general low avidity of 18 F-FDG for primary prostate cancer. Liu reported on a retrospective study of 9 men (mean serum PSA level, 291 ng/mL; SD, 363 ng/mL; range, 6.1-980 ng/mL) who underwent 18 F-FDG PET/CT at the time of initial staging of known primary prostate cancer (13) . The standard of reference for the PET observations was biopsy, regional diagnostic CT, or whole-body bone scan. Although the sensitivity of 18 F-FDG PET/CT for identifying primary cancer was only 33%, metastatic lymph nodes or bone lesions were also detected in 6 of the 9 patients. Liu concluded that, in general, 18 F-FDG PET/CT may not be useful for the detection of primary cancer but may be useful for initial staging in certain subgroups of patients with high serum PSA levels.
Beauregard et al. performed 18 F-FDG PET/CT for the staging workup of 44 patients with known Gleason sum scores of greater than or equal to 8 (i.e., aggressive tumors) (14) . Foci suggesting high 18 F-FDG uptake were found in the prostate gland, lymph nodes, and bone in 44%, 13%, and 6% of the patients, respectively. The absence or presence of intraprostatic 18 F-FDG uptake was associated with a median cancer-free survival probability of 70.2% or 26.9% (P 5 0.0097), respectively.
In the early analysis of the National Oncologic PET Registry data in the United States, involving 2,042 scans, for the initial staging of prostate cancer (the most common cancer type in the initial staging subgroup), 18 F-FDG PET/CT had an impact on clinical management in 32% (95% CI, 30.0%-34.1%) of the patients (15) .
Biochemical Recurrence
Localization of disease in patients with biochemical recurrence is essential, as it directs appropriate management, which may include salvage therapy with surgery or radiation for local recurrence, systemic therapy for metastatic disease, or both. The American Urologic Association defines biochemical recurrence in postprostatectomy patients as an initial serum PSA level of 0.2 ng/mL or higher, with a second, confirmatory level of greater than 0.2 ng/mL (16) . The American Society for Therapeutic Radiology and Oncology consensus definition for biochemical failure after primary external-beam radiotherapy is an increase of 2 ng/mL or more above the nadir PSA level, regardless of hormonal therapy (17) . Nonstandard imaging studies should only be considered when the results of standard imaging ( 99m Tc-based bone scintigraphy or contrast-enhanced abdomen and pelvis CT) are negative or equivocal. Multiparametric MRI is also typically used to scrutinize the prostate bed.
In a study of 18 F-FDG PET, a sensitivity of 75% and a specificity of 100% for the detection of pelvic lymph node metastases were reported; validation was based on histopathologic examination of the surgically harvested nodes (18) . Jadvar et al. reported the findings of a prospective investigation on the potential utility of 18 F-FDG PET/CT and 18 F-NaF PET/CT for the detection of occult metastases in 37 men with PSA relapse (range, 0.5-40.2 ng/mL) and strictly negative results on standard imaging studies (19) . The 18 F-FDG PET/CT detection rate was only 8.1% in the setting of biochemical recurrence. In another recent investigation, involving 28 patients with PSA relapse after definitive primary therapy (82.1% radical prostatectomy and 17.9% external-beam radiation therapy), the sensitivity and specificity of 18 F-FDG PET/ CT were 61.6% and 75%, respectively (20) . Schöder et al. reported a positive detection rate of 31% in this clinical setting (21) . In another comparative study of 18 F-FDG and 11 C-choline, the sensitivities of 11 C-choline and 18 F-FDG were 60.6% and 31%, respectively (22) . The sensitivities increased for both radiotracers, to 80% and 40%, respectively, when the serum PSA levels were greater than 1.9 ng/mL. On the basis of current experience, it appears that, in general, 18 F-FDG PET has limited utility in this clinical setting.
Response Assessment in Metastatic Disease
Prostate cancer is a remarkably heterogeneous disease; therefore, a personalized approach to tailored treatment is most desired. Such an approach demands surrogate imaging markers that can portray the disease activity accurately before, during, and after treatment as well as dependence on specific response criteria that are used in data analysis, such as RECIST 1.0, RECIST 1.1, or PERCIST 1.0 (23, 24) . Tumor 18 F-FDG uptake generally decreases with successful treatment (androgen deprivation or chemotherapy), although imaging findings may be discordant with those of other manifestations of disease, including changes in the levels of serum PSA or circulating tumor cells (25) .
Simoncic et al. compared dynamic 18 F-NaF and 18 F-FDG PET/CT for assessment of the response to zibotentan in men with bone metastases from prostate cancer (26) . Late (2-wk break after 4 wk of therapy, i.e., wk 6) 18 F-NaF and 18 F-FDG uptake responses were correlated, but earlier uptake responses (4 wk of therapy) were unrelated, suggesting that 18 F-NaF uptake and 18 F-FDG uptake in the setting of response assessment may be spatially disjointed and that these radiotracers may provide complementary information. Other studies have shown that 18 F-FDG uptake in metastatic lesions declines with successful androgen deprivation therapy or chemotherapy ( Fig. 1) (27, 28) . Although these preliminary studies are encouraging, there is clearly a need for additional experience in this clinical scenario.
Assessment of Prognosis
Recently, there has been increasing emphasis on the prognostic utility of various imaging studies in cancer, in terms of accuracy for the prediction of an outcome of interest, which can help with clinical management decisions and with assessment of the comparative effectiveness of various conventional and emerging treatment strategies. In the clinical setting of prostate cancer, these outcome measures may include, but are not limited to, time to biochemical recurrence (time to PSA progression), time to first metastasis, time to symptomatic progression, time to initiation of cytotoxic chemotherapy, time to radiographic progression, time to castration resistance state, progression-free survival, metastasis-free survival, disease-specific survival, and overall survival (29) .
In 18 F-FDG PET/CT, and were then monitored for overall survival (32) . In the multivariate analysis after adjustment for prognostic clinical confounders (age, serum PSA level, serum alkaline phosphatase level, use of pain medication, prior chemotherapy, and Gleason score at initial diagnosis), the sum of the SUV max for up to 25 metabolically active lesions (lymph node, bone, and soft-tissue metastases) was statistically significant, with a hazard ratio of 1.01 (95% CI, 1.001-1.020; P 5 0.053), for predicting overall survival. Specifically, the moving hazard of death in relation to the sum of the SUV max , interpreted as the chance of death per person per month, showed a marked upward shift of the curve (i.e., increased chance of death) for a sum of the SUV max of greater than 20.
In another retrospective investigation, the association of CT patterns and glycolytic activity of prostate cancer bone metastases with overall survival was investigated in 38 patients (33) . The number of lesions on CT or 18 F-FDG PET, but not the intensity of 18 F-FDG uptake, was associated with overall survival.
Aside from differences in methodology between the study of Jadvar et al. and the study of Vargas et al., the central hypothesis remains the same: that both the number of lesions and the intensity or aggressiveness of the "worst" lesion will be independent prognostic variables (34) .
CELLULAR PROLIFERATION
The imaging of cellular proliferation provides valuable information about the rate of tumor growth, which can be important in tumor characterization (e.g., indolent vs. aggressive), and early assessment of the response to therapy (35) . PET in conjunction with radiotracers that track the thymidine salvage pathway of DNA synthesis has been studied for the noninvasive imaging-based assessment of cellular proliferation in cancer (36) (37) (38) . Experience with 2 radiotracers that have been used in preclinical and pilot clinical studies of prostate cancer, 39-deoxy-39-18 F-fluorothymidine ( 18 F-FLT) and 29-18 F-fluoro-5-methyl-1-b-D-arabinofuranosyluracil ( 18 F-FMAU), is briefly highlighted here (Fig. 2) .
F-FLT
18 F-FLT is the most studied cellular proliferation PET tracer. It is phosphorylated by thymidine kinase 1, is retained in proliferating cells without DNA incorporation, and can be described with a 3-compartment model (39, 40) . Normal biodistribution is characterized by relatively high uptake in the liver and bone marrow, with the urinary bladder receiving the highest dose through renal excretion (41) . Other than data from a few preclinical animal studies, few data on the potential utility of 18 F-FLT in human prostate cancer are available, perhaps because of the high physiologic localization of 18 F-FLT in normal bone marrow-the most common site for prostate tumor metastases. Nevertheless, a preclinical micro-PET study demonstrated a significant decline in 18 F-FLT uptake after docetaxel treatment in 22Rv1 hormonerefractory prostate tumors Normal biodistribution of 18 F-FMAU. Note relatively high tracer uptake in liver and renal cortex; moderate uptake in salivary glands, thyroid, heart, spleen, and urinary bladder; and relatively low uptake in bone marrow.
implanted in athymic mice (42) . The conclusion was that 18 F-FLT might be a useful tracer for the early assessment of anticancer therapy with docetaxel in patients with castration-resistant prostate cancer.
F-FMAU
18 F-FMAU is phosphorylated by thymidine kinase and incorporated into DNA (43) . Tehrani et al. showed that this thymidine analog was preferentially phosphorylated by mitochondrial thymidine kinase 2 rather than cytosolic thymidine kinase 1 (44) . The fact that 18 F-FMAU shows little accumulation in bone renders it an ideal PET radiotracer in prostate cancer (Fig. 3) (45) . Jadvar et al. showed that there may be an association between androgen signaling and thymidine metabolism and that 18 F-FMAU PET may be useful in prostate tumor characterization (46) . A possible explanation may be the androgen control of mitochondrial function, which may include thymidine kinase 2 enzymatic activity (47) . A pilot observational study of 18 F-FMAU PET in 3 men with prostate cancer confirmed the tumor retention of 18 F-FMAU in local prostate recurrence and in metastatic lesions with barely visible activity in the urinary bladder and normal bone (48) . Moreover, on average, 95% of the blood activity cleared within 10 min after 18 F-FMAU administration, and about 70% of the activity in the urine was intact 18 F-FMAU at 60 min after injection. Jadvar et al. also recently initiated a pilot study to assess the potential utility of 18 F-FMAU in image-targeted biopsy with software-based fusion of PET, transrectal ultrasound, and multiparametric MRI of the prostate gland (Fig. 4) (49) . This hybrid imaging methodology may allow for improved localization and characterization of tumors for targeted biopsy and focal therapy (50) .
CONCLUSION
Incidental high focal 18 F-FDG uptake in the prostate gland is rare but may identify previously unknown prostate tumors. 18 F-FDG PET is generally not useful for staging known disease and has limited value in patients with biochemical recurrence. Castrationresistant metastatic disease is often metabolically active, and limited evidence currently suggests that 18 F-FDG PET may be useful for assessment of treatment response and prognosis. Imaging of cellular proliferation with 18 F-FMAU may allow for the localization of aggressive primary tumors, which may then be amenable to focal therapy of localized prostate cancer.
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